BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

941 related articles for article (PubMed ID: 23684942)

  • 1. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
    Lei Z; Tan IB; Das K; Deng N; Zouridis H; Pattison S; Chua C; Feng Z; Guan YK; Ooi CH; Ivanova T; Zhang S; Lee M; Wu J; Ngo A; Manesh S; Tan E; Teh BT; So JB; Goh LK; Boussioutas A; Lim TK; Flotow H; Tan P; Rozen SG
    Gastroenterology; 2013 Sep; 145(3):554-65. PubMed ID: 23684942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
    Fukuda H; Takiguchi N; Koda K; Oda K; Seike K; Miyazaki M
    Cancer Invest; 2006; 24(3):235-41. PubMed ID: 16809149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer.
    Fakhrejahani E; Miyamoto A; Tanigawa N
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):437-46. PubMed ID: 17377791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer.
    Ivanova T; Zouridis H; Wu Y; Cheng LL; Tan IB; Gopalakrishnan V; Ooi CH; Lee J; Qin L; Wu J; Lee M; Rha SY; Huang D; Liem N; Yeoh KG; Yong WP; Teh BT; Tan P
    Gut; 2013 Jan; 62(1):22-33. PubMed ID: 22535375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer.
    Jeung HC; Rha SY; Shin SJ; Lim SJ; Roh JK; Noh SH; Chung HC
    Anticancer Drugs; 2011 Sep; 22(8):801-10. PubMed ID: 21572321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
    Salonga D; Danenberg KD; Johnson M; Metzger R; Groshen S; Tsao-Wei DD; Lenz HJ; Leichman CG; Leichman L; Diasio RB; Danenberg PV
    Clin Cancer Res; 2000 Apr; 6(4):1322-7. PubMed ID: 10778957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
    Tahara M; Ochiai A; Fujimoto J; Boku N; Yasui W; Ohtsu A; Tahara E; Yoshida S
    Oncol Rep; 2004 Jan; 11(1):9-15. PubMed ID: 14654896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
    Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico analysis of stomach lineage specific gene set expression pattern in gastric cancer.
    Pandi NS; Suganya S; Rajendran S
    Biochem Biophys Res Commun; 2013 Oct; 439(4):539-46. PubMed ID: 24025679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T
    J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
    Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy.
    Faried LS; Faried A; Kanuma T; Aoki H; Sano T; Nakazato T; Tamura T; Kuwano H; Minegishi T
    Mol Carcinog; 2008 Jun; 47(6):446-57. PubMed ID: 18058806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.
    Oeda M; Yoshida K; Sanada Y; Wada Y; Suzuki T; Mizuiri H; Konishi K; Shigematsu H; Tanabe K; Fukushima M
    Oncol Rep; 2006 Dec; 16(6):1165-72. PubMed ID: 17089033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding the Lauren classification: a new gastric cancer subtype?
    Turner ES; Turner JR
    Gastroenterology; 2013 Sep; 145(3):505-8. PubMed ID: 23891604
    [No Abstract]   [Full Text] [Related]  

  • 17. Classification of gastric cancer subtypes using ICA, MLR and Bayesian network.
    Ishii H; Sasaki H; Aoyagi K; Yamazaki T
    Stud Health Technol Inform; 2013; 192():1014. PubMed ID: 23920788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
    Jhawer M; Coit D; Brennan M; Qin LX; Gonen M; Klimstra D; Tang L; Kelsen DP; Shah MA
    Am J Clin Oncol; 2009 Aug; 32(4):356-62. PubMed ID: 19381079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dihydropyrimidine dehydrogenase correlates with prolonged survival in patients with lung adenocarcinoma treated with 5-fluorouracil.
    Shintani Y; Inoue M; Funakoshi Y; Matsumura A; Ohta M; Maeda H; Okumura M
    Anticancer Res; 2011 Dec; 31(12):4665-71. PubMed ID: 22199347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.